Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

MRT-6160

Small molecule · developed by Monte Rosa Therapeutics

Phase 1 Most advanced trial (none active)

GLUE Developer

1 Registered trials

What is MRT-6160?

MRT-6160 is an investigational small-molecule drug studied in Healthy Volunteers.

At a glance

Drug type: Small molecule
Developer: Monte Rosa Therapeutics, Inc (GLUE)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06597799	Phase 1	Healthy Volunteers	Completed	GLUE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteers

More from Monte Rosa Therapeutics

MRT-2359 Phase 1/2 MRT-8102 Phase 1

Sources

ClinicalTrials.gov NCT06597799

Updated Oct 3, 2026. Something wrong or missing? Report it on the GLUE page.

Follow GLUE, the company behind MRT-6160

See GLUE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GLUE catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z